OptiHER-Heart: A Prospective, Multicenter, Single-arm, Phase II Study to Evaluate the Safety of Neoadjuvant Liposomal Doxorubicin (Myocet) Plus Paclitaxel, Trastuzumab, and Pertuzumab in Patients With HER2-positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Acronyms Opti-HER; OptiHerHEART
- 10 Jun 2017 Biomarkers information updated
- 21 Apr 2016 Status changed from active, no longer recruiting to completed.
- 23 Dec 2013 Planned end date changed from 1 May 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.